According to a recent study published online early in the International Journal of Hematology, researchers have found that adjusting the starting dose of lenalidomide according to renal function did not compromise the efficacy or safety of lenalidomide plus low-dose dexamethasone in Chinese patients with advanced relapsed and/or refractory multiple myeloma and renal impairment.
For the study, researchers conducted a subgroup analysis of the MM-021 trial to assess the efficacy and safety of lenalidomide plus low-dose dexamethasone in Chinese patients with advanced relapsed or refractory multiple myeloma and renal impairment.
Researchers classified patients as having either no/mild renal impairment (CrCl ≥60mL/min), moderate impairment (CrCl ≥30 to <60 mL/min), or severe renal impairment (CrCl <30 mL/min).
RELATED: Carfilzomib Superior to Bortezomib for Relapsed Multiple Myeloma
Patients received lenalidomide at a starting dose of 25 mg/day on days 1-21, which was adjusted for baseline renal function. Patients received the regimen until disease progression or discontinuation.
Results showed response rates for mild, moderate, and severe impairment were 50%, 42%, and 42%, respectively. Patients with no/mild renal impairment experience a longer median progression-free survival and overall survival compared with those with moderate or severe renal impairment.
In regard to safety, grade 3-4 anemia, neutropenia, and thrombocytopenia were more common in patients with severe renal impairment.